Merck in-licenses Celera RNAi targets

Celera (NYSE:CRA) granted Merck (NYSE:MRK) two years of exclusive access to up to 10 cancer targets to develop RNAi-based therapeutics. Celera will receive an upfront payment and is eligible for devel...